Back

Stop Covid 2 Trial

Official Title

Fluvoxamine for early treatment of COVID-19: A fully-remote, randomized placebo controlled trial.

Study Details

This trial aims to slow the progression of COVID-19 and prevent hospitalization, it will compare fluvoxamine to a placebo (a sugar pill without active medication). The study is contactless meaning volunteers can participate without leaving home.

Principal Investigator

Dr. Eric Lenze

IRB Number

202011101

Eligibility

1. Participants must be age 18 or older and must have tested positive for COVID-19
2. Participants must be experiencing symptoms of COVID-19
3. Participants must not have been vaccinated for COVID-19

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back